Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib levels in semen in men with chronic myeloid leukemia
NL-OMON26150Recruiting
- Sponsor
- VU University Medical Center
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by VU University Medical Center. Primary endpoint: Percentage of nilotinib present in seminal fluid in relation to the plasma concentration. Started Dec 2017; status: recruiting.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON26150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26150.